TriangleHEALTH PROFESSIONAL · SOURCE READING
Other drug therapy
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[38]
Source links and citations
Bexarotene, an oral or topical retinoid (NCT00255801).[39,40]
Source links and citations
Lenalidomide.[41]
Source links and citations
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[23,42-44][Level of evidence C3]
Source links and citations
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[23,42-44][Level of evidence C3]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[23][Level of evidence C3]
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice